Decibel Therapeutics, Inc. (DBTX) [Rocket]

In millions, except per share items	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18
	10-K	10-K	10-K	S-1/A
Revenues	0.0	39.9	29.4	26.2
Revenue growth	-100.0%	35.6%	12.4%
Cost of goods sold	0.0	0.0	44.1	37.9
Gross profit	0.0	39.9	-14.7	-11.7
Gross margin		100.0%	-49.9%	-44.7%
Selling, general and administrative [+]	20.4	14.2	14.7	11.7
General and administrative	20.4	14.2	14.7	11.7
Research and development	29.8	25.3
Other operating expenses		39.6	14.7	14.5
EBITDA [+]	-48.8	-37.6	-42.3	-36.4
EBITDA growth	29.8%	-11.1%	16.3%
EBITDA margin		-94.4%	-143.9%	-139.0%
Depreciation and amortization	1.4	1.6	1.8	1.5
EBIT [+]	-50.2	-39.3	-44.1	-37.9
EBIT growth	27.9%	-10.9%	16.4%
EBIT margin		-98.5%	-149.9%	-144.7%
Non-recurring items [+]		0.3
Asset impairment		0.3
Interest income	0.2	0.1
Interest income	0.2	0.1
Other income (expense), net [+]	0.0	0.2	1.4	1.7
Other non-operating income	0.0	0.2
Other	0.0	0.2
Pre-tax income	-50.0	-39.3	-42.7	-36.2
Income taxes	1.8	0.0	0.0	0.0
Tax rate		0.0%	0.0%	0.0%
Net income	-54.1	-35.3	-42.7	-36.2
Net margin		-88.5%	-145.1%	-138.2%

Basic EPS [+]	($2.49)	($19.65)	($0.12)	($0.15)
Growth	-87.3%	16943.9%	-21.1%
Diluted EPS [+]	($2.49)	($19.65)	($0.12)	($0.15)
Growth	-87.3%	16943.9%	-21.1%

Shares outstanding (basic) [+]	21.7	1.8	370.1	247.4
Growth	1110.2%	-99.5%	49.6%
Shares outstanding (diluted) [+]	21.7	1.8	370.1	247.4
Growth	1110.2%	-99.5%	49.6%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.